Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 27 October 2006:
Vol. 314. no. 5799, p. 577
DOI: 10.1126/science.314.5799.577d
Prev | Table of Contents | Next

ScienceScope

The $10 million Cancer Genome project, announced last week, marks China's first large-scale research program targeting a specific clinical disease. The program focuses on variations at the structural genomic and sequence levels, epigenomics, and transcriptomics, says Yang Huanming, director of the Beijing Genomics Institute. The program will carry out research into cancers that are prevalent in China, which could include lung, liver, stomach, and esophageal cancers. U.S. National Cancer Institute official Daniela Gerhard calls the project "a good idea," noting China's unique tumor samples. Although China is a partner in the international Human Genome and HapMap projects, Gerhard says the United States will wait for more details before considering partnering on the latest effort.




To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)